Is there any adjustment to the latest price of Lazertinib in 2025?

As of2025, Lazertinib (Lazertinib, also known as Lazcluze®) has not yet been officially priced and sold in China, and is mainly supplied through clinical trials or specific hospital channels; therefore, there is no official public price. According to the press conferences of international and domestic pharmaceutical companies and academic discussions, the industry generally expects that its price will be higher after it is launched, but it is expected to be further discounted after it is included in the medical insurance system.

Internationally, lanzitinib has been approved by South Korea, the United States in 2024 and the European Union in early 2025. Its market price for EGFR mutation-positive intermediate and advanced non-small cell lung cancer is generally high. For example, international academic literature mentions that the drug cost per cycle of single drug or combination therapy ranges from 1.3 to 2.4USD (approximately 9-17 RMB). This means that even if it is introduced into the country, the price of its unsubsidized original drug is expected to be higher than tens of thousands of yuan per box.

Considering the practice of domestic medical insurance negotiations, many people expect the price of lanzetinib to drop to a reasonable range. If it is eventually included in medical insurance, the patient's out-of-pocket payment may range from a few thousand to more than 10,000 yuan. This will help improve accessibility, especially for patients with limited financial means. The specific reimbursement ratio and drug cost burden still need to wait for feedback from regional medical policies after the official launch.

It is recommended to pay attention to subsequent launch information and consult the attending doctor or hospital pharmacy:① Determine the manufacturer's domestic guide price after the product is launched; ② Understand the status and reimbursement levels of local medical insurance catalogs; ③ Combine your own illness and economic status to determine whether to participate in insurance subsidies or join patient support projects. Only by combining policy dynamics and actual channel information can we accurately grasp the final drug purchase cost and feasibility of use of Lanzertinib.

Reference materials:https://www.drugs.com